Asset Details
Do you wish to reserve the book?
Medical management of gastric cancer: a 2017 update
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Medical management of gastric cancer: a 2017 update
Do you wish to request the book?
Medical management of gastric cancer: a 2017 update
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Medical management of gastric cancer: a 2017 update
2018
Overview
Gastric cancer remains a considerable health burden throughout the world. The Cancer Genome Atlas (TCGA) analysis has recently unveiled 4 genotypes of gastric cancer with data not ready to change treatment strategy yet. A multimodality approach to therapy is the cornerstone of screening, diagnosing, staging, treating and supporting patients with gastric cancer. The evidence‐based approach to localized gastric cancer (>cT1b) is to use an either preoperative or postoperative strategy to maximize the benefit of surgery. The focus of future research is to optimize chemotherapy regimens, determine the role of radiation therapy and investigate the effect of treatment timing. In metastatic gastric cancer, biologic therapies have been introduced targeting markers shown to be prognostic. The results of ongoing randomized controlled phase 3 trials using targeted and immunotherapy agents, either in combination or alone, have the potential to alter the current treatment landscape of advanced gastric cancer. A multimodality approach to therapy is critical for patients with gastric cancer. One of the most challenging and exciting field that appears promising is the potential of host's immune system to inhibit signaling pathways.
Publisher
John Wiley & Sons, Inc,John Wiley and Sons Inc
Subject
Antineoplastic Combined Chemotherapy Protocols - pharmacology
/ Antineoplastic Combined Chemotherapy Protocols - therapeutic use
/ Biomarkers, Tumor - antagonists & inhibitors
/ Biomarkers, Tumor - genetics
/ Chemotherapy, Adjuvant - methods
/ Clinical Trials, Phase III as Topic
/ Genomes
/ Humans
/ Molecular Targeted Therapy - methods
/ multimodality treatment approach
/ Randomized Controlled Trials as Topic
/ Review
/ Stomach Neoplasms - epidemiology
/ Stomach Neoplasms - genetics
/ Surgery
